Novartis Willful Patent Infringement Claims Dismissed In New York
NEW YORK — A New York federal judge on Oct. 24 found that allegations of willful infringement levied in connection with patented gene expression technology fail to state a claim (Novartis...To view the full article, register now.
Already a subscriber? Click here to view full article